| Literature DB >> 33963206 |
M Abend1, S A Amundson2, C Badie3, K Brzoska4, R Hargitai5, R Kriehuber6, G O'Brien3, S Schüle7, E Kis5, S A Ghandhi2, K Lumniczky5, S R Morton2, D Oskamp6, P Ostheim7, C Siebenwirth7, I Shuryak2, T Szatmári5, M Unverricht-Yeboah6, E Ainsbury8, C Bassinet9, U Kulka10, U Oestreicher10, Y Ristic9, F Trompier9, A Wojcik11, L Waldner12, M Port7.
Abstract
Large-scale radiation emergency scenarios involving protracted low dose rate radiation exposure (e.g. a hidden radioactive source in a train) necessitate the development of high throughput methods for providing rapid individual dose estimates. During the RENEB (Running the European Network of Biodosimetry) 2019 exercise, four EDTA-blood samples were exposed to an Iridium-192 source (1.36 TBq, Tech-Ops 880 Sentinal) at varying distances and geometries. This resulted in protracted doses ranging between 0.2 and 2.4 Gy using dose rates of 1.5-40 mGy/min and exposure times of 1 or 2.5 h. Blood samples were exposed in thermo bottles that maintained temperatures between 39 and 27.7 °C. After exposure, EDTA-blood samples were transferred into PAXGene tubes to preserve RNA. RNA was isolated in one laboratory and aliquots of four blinded RNA were sent to another five teams for dose estimation based on gene expression changes. Using an X-ray machine, samples for two calibration curves (first: constant dose rate of 8.3 mGy/min and 0.5-8 h varying exposure times; second: varying dose rates of 0.5-8.3 mGy/min and 4 h exposure time) were generated for distribution. Assays were run in each laboratory according to locally established protocols using either a microarray platform (one team) or quantitative real-time PCR (qRT-PCR, five teams). The qRT-PCR measurements were highly reproducible with coefficient of variation below 15% in ≥ 75% of measurements resulting in reported dose estimates ranging between 0 and 0.5 Gy in all samples and in all laboratories. Up to twofold reductions in RNA copy numbers per degree Celsius relative to 37 °C were observed. However, when irradiating independent samples equivalent to the blinded samples but increasing the combined exposure and incubation time to 4 h at 37 °C, expected gene expression changes corresponding to the absorbed doses were observed. Clearly, time and an optimal temperature of 37 °C must be allowed for the biological response to manifest as gene expression changes prior to running the gene expression assay. In conclusion, dose reconstructions based on gene expression measurements are highly reproducible across different techniques, protocols and laboratories. Even a radiation dose of 0.25 Gy protracted over 4 h (1 mGy/min) can be identified. These results demonstrate the importance of the incubation conditions and time span between radiation exposure and measurements of gene expression changes when using this method in a field exercise or real emergency situation.Entities:
Mesh:
Year: 2021 PMID: 33963206 PMCID: PMC8105310 DOI: 10.1038/s41598-021-88403-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Typical calibration curves I (A) and II (B) were generated using two radiation-induced genes (FDXR and DDB2) and exposures as shown in the Table to the bottom right. Unexposed samples incubated over 8 h at 37 °C showed constant gene expression values over time (C) indicating that the reference of 0 Gy incubated over 8 h will not introduce a bias in samples irradiated over a shorter period of time as shown in the Table for calibration curve I. Symbols represent mean gene expression values from technical replicates. Error bars represent standard deviation of duplicate measurements and are visible when larger than the symbols. Calibration curves were generated before the exercise (n = 6) and those shown herein represent typical examples (graph created using SigmaPlot Version 14.0, http://www.systatsoftware.com).
Overview of participating teams, their institutions, and an overview of their contribution for the RENEB 2019 exercise comprising the platform used as well as the genes, calibration samples and further details.
| Institution | Platform | # Genes | Gene name | Prerequisites |
|---|---|---|---|---|
| Cancer Mechanisms and Biomarkers, Radiation Effects Dept, Centre for Radiation, Chemical and Environmental Hazards, Public Health England (PHE), Chilton, UK | qRT-PCR | 1 | FDXR | Blind samples, calibration curves I and II |
| Radiation Medicine Unit, National Public Health Center (NPHC), Budapest, Hungary | qRT-PCR | 2 | FDXR, DDB2 | Blind samples, calibration curves I and II, samples were processed by 3 colleagues |
| Institute of Nuclear Chemistry and Technology (INCT), Warsaw, Poland | qRT-PCR | 8 | BAX, BBC3, CDKN1A, DDB2, FDXR, GADD45A, GDF15, TNFSF4 | Blind samples, calibration curves I and II, additional calibration curve (generated in INCT) |
| Radiation Biology Unit, Department of Safety and Radiation Protection, Forschungszentrum Jülich GmbH (FZJ), Jülich, Germany | Microarrays | 7 resp. 2 | TNFSF4, FDXR, DOK7, SPATA18, PHLDA3, LINC00475, VWCE resp. TNSF4, FDXR | Blind samples, inhouse controls, assumption: sample 3A = control |
| Columbia University Irving Medical Center (CUIMC), New York, NY | qRT-PCR | 5 | CDKN1A, GDF15, FDXR, DDB2, PCNA | Blind samples, calibration curves I and II |
| Bundeswehr Institute of Radiobiology (BIR), Munich, Germany | qRT-PCR | 2 | FDXR, DDB2 | Blind samples, calibration curves I and II |
Figure 2The coefficient of variation (CV) was calculated based on all available technical replicates and genes. The distribution of CVs per gene is reflected by a box plot showing the 10th (lower whisker), 25th (lower end of the box), 50th (median, straight line), 75th (upper end of the box) and 90th (upper whisker) percentiles. Genes are ordered with increasing normalized Ct-values. Teams are arbitrarily numbered from one to five. The horizontal spotted grey line refers to the 15% CV and shows that most measurements are lying below this value (graph created using SigmaPlot Version 14.0, http://www.systatsoftware.com).
Overview of methodological details of either qRT-PCR or microarrays used by the contributing teams.
| Workflow | qRT-PCR | ||||
|---|---|---|---|---|---|
| PHE | NPHC | INCT | CUMC | BIR | |
| Isolation kit | n.a | n.a | n.a | n.a | QIAamp RNA Blood Mini Kit |
| DNA digestion during isolation | RNase-free DNase-Set (Qiagen) | ||||
| Template eluted in: | RNAse-free water | ||||
| Quality control | |||||
| RNA integrity number | Yes | ||||
| RNA concentration | Yes (NanoDrop ™) | ||||
| A260/280 | Yes | ||||
| A260/230 | Yes | ||||
| Check DNA contamination | conventional PCR (ß-actin primer, HotStar MasterMix (Qiagen), 30 cycles) | ||||
| Kit/MasterMix | High capacity cDNA archive kit | RevertAid First Strand cDNA Synthesis Kit | High Capacity cDNA Reverse Transcription Kit | High-Capacity cDNA Reverse Transcription Kit | High capacity cDNA archive kit |
| PCR protocol | 1×/25 °C/10 min, 1×/37 °C/120 min, 1×/85 °C/5 min | 1×/25 °C/5 min, 1×/42 °C/60 min, 1×/70 °C/5 min | 1×/25 °C/10 min, 1×/37 °C/120 min, 1×/85 °C/5 min | 1×/25 °C/10 min, 1×/37 °C/120 min | 1×/25 °C/10 min, 1×/37 °C/120 min |
| Quality control | HPRT1 Ct | 18S rRNA Ct | ITFG1 Ct, DPM1 Ct | XXX | 18S rRNA Ct |
| Kit/MasterMix | TaqMan,PerfeCTa®, MultiPlex qPCR SuperMix, Quanta bioscience | TaqMan fast advanced master mix | TaqMan Universal Master Mix II | TaqMan Universal Master Mix | TaqMan Universal Master Mix |
| TaqMan assay | FDXR, no. HS01031617_m1 | DDB2 (Hs00172068_m1), FDXR (HS01031617_m1), 18SrRNA (Hs99999901_s1) | BAX (Hs00180269_m1), BBC3 (Hs00248075_m1), CDKN1A (Hs00355782_m1), DDB2 (Hs03044953_m1), FDXR (Hs00244586_m1), GADD45A (Hs00169255_m1), GDF15 (Hs00171132_m1), TNFSF4 (Hs00182411_m1), ITFG1 (Hs00229263_m1), DPM1 (Hs00187270_m1) | CDKN1A (Hs00355782_m1), DDB2 (Hs03044953_m1), FDXR (Hs00244586_m1), GDF15 (Hs00171132_m1), PCNA (Hs00696862_m1) | DDB2 (Hs00172068_m1), FDXR (HS01031617_m1) |
| Cycles | 1×/95 °C/2 min, 40×/95 °C/10 s, 60 °C/1 min | 1×/50 °C/2 min, 1×/95 °C/20 s, 40×/95 °C/3 s, 60 °C/30 s | 1×/95 °C/10 min, 40×/95 °C/15 s, 60 °C/1 min | 1×/50 °C/2 min, 95 °C/10 min, 40×/95 °C/15 s, 60 °C/1 min | 1×/50 °C/2 min, 1x/95 °C/10 min, 40×/95 °C/1 min, 60 °C/1 min |
| Detection system | Rotor Gene Q (Qiagen) | Rotor-Gene Q (Qiagen) | 7500 Real-Time PCR System (Thermo Fischer Scientific) | QIA-7 | GeneAmp 7900 |
| Threshold | fixed | fixed | fixed | 0.05 | automatic |
| Normalization | HPRT1 | 18S rRNA | ITFG1 and DPM1 (geometric mean) | UBC | Human 18S rRNA |
| Quantification method | D-Ct approach | DD-Ct method, relative fold change in relation to the 0 Gy sample of the Calibration curve | D-Ct approach | Relative Quantification | D-Ct approach |
| Quality control | |||||
| Standard curve | Yes | No | No | NA | Yes |
| Slope | Yes | No | No | NA | Yes |
| r2 | Yes | No | No | NA | Yes |
| 18s rRNA Ct | HPRT1, (–)RT and NTC | 18S rRNA Ct, NTC | ITFG1, DPM1, NTC | NA | Yes |
The sequence of topics from top to bottom reflect a typical workflow for gene expression analysis starting with the isolation of RNA, quality and quantity controls, cDNA synthesis and qRT-PCR.
The reported dose estimates from teams running qRT-PCR or microarrays are shown for each blinded sample irradiated with a known (true) dose, which is shown in parenthesis in the subtitles.
| Teams | Calibration curves used | Method | Reported dose estimates (Gy) | |||
|---|---|---|---|---|---|---|
| 1A (true dose, 2.4 Gy) | 1B (true dose, 0.18 Gy) | 2A (true dose, 1.6 Gy) | 3A (true dose, 0.25 Gy) | |||
| 1 | FDXR and calibration curve I | qRT-PCR | 0.13 | 0.05 | 0.15 | 0.04 |
| FDXR and calibration curve II | 0.04 | 0.02 | 0.05 | 0.02 | ||
| 2 | FDXR and calibration curve I, 3 individuals measured | qRT-PCR | 0.11 | 0.13 | 0.14 | 0.09 |
| DDB2 and calibration curve I, 3 individuals measured | 0.29 | 0.34 | 0.41 | 0.33 | ||
| FDXR and calibration curve II, 3 individuals measured | < 0.125 | < 0.125 | < 0.125 | < 0.125 | ||
| DDB2 and calibration curve II, 3 individuals measured | < 0.125 | < 0.125 | < 0.125 | < 0.125 | ||
| 3 | 8 signature genes + three calbration curves | qRT-PCR | 0.09 | 0.04 | 0.13 | 0.01 |
| 4 | 7-genes, inhouse calibration curves; assumption: sample 3A = control | microarrays | 0.25 | 0.8 | 0.25 | 0 |
| 2-genes, inhouse calibration curves; assumption: sample 3A = control | 0.1 | 0.2 | 0.05 | 0 | ||
| 5 | 5 signature genes + both calibration curves used | qRT-PCR | 0.3 | 0.2 | 0.3 | 0.2 |
| 6 | FDXR and calibration curve I | qRT-PCR | 0 | 0 | 0 | 0 |
| FDXR and calibration curve II | 0–0.2 | 0 | 0 | 0 | ||
| DDB2 and calibration curve I | 0.63 | 0 | 0 | 0 | ||
| DDB2 and calibration curve II | 0.22 | 0 | 0.17 | 0 | ||
Use of different calibration curves and genes generates several dose estimates per team.
Figure 3Examples of calibration curves I (A,C) and II (E,F) and additional calibration curves combined (B,D) generated by the different qRT-PCR teams are shown. Gene expression reflected either as differential gene expression (reference was the 0 Gy calibration sample, A), normalized single genes from two different teams (C,E,F), averaged (B) or summed Ct-values (D) using several genes combined were plotted versus radiation dose (Gy). Normalized and differential gene expression values measured below 0.5–1.0 Gy (calibration curve I) and 0.125 Gy (calibration curve II) were fitted with a horizontal line (assuming a threshold) and higher values using a manual fit. For summed normalized Ct-values of 8 genes (BAX, BBC3, CDKN1A, DDB2, FDXR, GADD45A, GDF15, TNFSF4) and utilizing different calibration curves an exponential fit was used and the 95% confidence intervals were plotted using a dotted line. As an example a linear-quadratic fit was used in (B) (details are presented in Supplemental File 1). Error bars represent standard deviation from duplicate measurements except for (A), where duplicate measurements were performed by each of three different individuals. Error bars are visible when larger than the symbols. Blinded samples 1A, 1B, 2A and 3A corresponding to the team’s calibration curve are superimposed in the panels and sometimes overlapping each other, because of very similar values (graph created using SigmaPlot Version 14.0, http://www.systatsoftware.com).
Figure 4The box plot reflects the absolute difference of all reported dose estimates from all teams relative to the mean reported dose value per blind sample. The box plot shows the 10th (lower whisker), 25th (lower end of the box), 50th (median, straight line), 75th (upper end of the box) and 90th (upper whisker) percentiles (graph created using SigmaPlot Version 14.0, http://www.systatsoftware.com).
Figure 5Differential gene expression changes of the blinded samples for each team were calculated relative to the 0 Gy samples of the calibration curve I for inter-comparison purposes. White bars represent the fold-changes for the genes used for dose estimation of the blinded samples (1A, 1B, 2A and 3A) by different teams arbitrarily numbered 1–5 (A) and 1–4 (B). Exposure time was 1 h and 2 h for the blinded samples with no additional time allowed for gene expression to respond. When using blinded samples with an adjusted exposure and incubation time of 4 h combined, much larger gene expression changes were observed (dark grey bar), more in line with previous reports at these doses. Results are shown for FDXR (A) and DDB2 (B). The observed changes in gene expression follow a linear fit of FDXR and a linear-quadratic fit of DDB2 with absorbed dose (C). Error bars represent the standard error of the mean and bars/dots the mean from replicate measurements (graph created using SigmaPlot Version 14.0, http://www.systatsoftware.com).
Figure 6Changes in differential gene expression (DEG) of DDB2 (upper graph) and FDXR (lower graph) relative to 37° C (calibrator) were examined at a range of temperatures between 27 and 39 °C with an additional 3 h incubation time at corresponding temperatures. Symbols are average gene expression fold changes and error bars are SEM (standard error of the mean) from two independent experiments on two blood samples with two technical replicates (total n = 8) (graph created using SigmaPlot Version 14.0, http://www.systatsoftware.com).